{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T16:24:36Z","timestamp":1777134276141,"version":"3.51.4"},"reference-count":217,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Warsaw"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>One of the main causes of heart failure is cardiomyopathies. Among them, the most common is hypertrophic cardiomyopathy (HCM), characterized by thickening of the left ventricular muscle. This article focuses on HCM and other cardiomyopathies with myocardial hypertrophy, including Fabry disease, Pompe disease, and Danon disease. The genetics and pathogenesis of these diseases are described, as well as current and experimental treatment options, such as pharmacological intervention and the potential of gene therapies. Although genetic approaches are promising and have the potential to become the best treatments for these diseases, further research is needed to evaluate their efficacy and safety. This article describes current knowledge and advances in the treatment of the aforementioned cardiomyopathies.<\/jats:p>","DOI":"10.3390\/ijms241713239","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T01:56:57Z","timestamp":1693187817000},"page":"13239","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6965-434X","authenticated-orcid":false,"given":"Anna","family":"Burban","sequence":"first","affiliation":[{"name":"First Department of Cardiology, Medical University of Warsaw, ul. Banacha 1A, 02-097 Warszawa, Poland"},{"name":"Doctoral School, Medical University of Warsaw, 81 \u017bwirki i Wigury Street, 02-091 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0143-7115","authenticated-orcid":false,"given":"Szymon","family":"Pucy\u0142o","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Medical University of Warsaw, ul. Banacha 1A, 02-097 Warszawa, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Sikora","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Medical University of Warsaw, ul. Banacha 1A, 02-097 Warszawa, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Opolski","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Medical University of Warsaw, ul. Banacha 1A, 02-097 Warszawa, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Grabowski","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Medical University of Warsaw, ul. Banacha 1A, 02-097 Warszawa, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Ko\u0142odzi\u0144ska","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Medical University of Warsaw, ul. Banacha 1A, 02-097 Warszawa, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","article-title":"Hypertrophic cardiomyopathy: Present and future, with translation into contemporary cardiovascular medicine","volume":"64","author":"Maron","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","unstructured":"Arbelo, E., Protonotarios, A., Gimeno, J.R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C.R., Biagini, E., Blom, N.A., and de Boer, R.A. (2023). 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur. Heart J., 1\u2013124."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchf.2017.09.011","article-title":"Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamacardio.2015.0354","article-title":"How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice","volume":"1","author":"Maron","year":"2016","journal-title":"JAMA Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)","volume":"35","author":"Jichi","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.108.804617","article-title":"Sudden deaths in young competitive athletes: Analysis of 1866 deaths in the United States, 1980\u20132006","volume":"119","author":"Maron","year":"2009","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/ncpcardio0859","article-title":"\u2018End-stage\u2019 hypertrophic cardiomyopathy: From mystery to model","volume":"4","author":"Yacoub","year":"2007","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0735-1097(03)00827-1","article-title":"Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients","volume":"42","author":"Monserrat","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.hrthm.2021.01.019","article-title":"Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator","volume":"18","author":"Maron","year":"2021","journal-title":"Heart Rhythm"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/europace\/eup431","article-title":"Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Systematic review of clinical risk markers","volume":"12","author":"Christiaans","year":"2010","journal-title":"Europace"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review","volume":"79","author":"Maron","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"722340","DOI":"10.3389\/fcvm.2021.722340","article-title":"Hypertrophic Cardiomyopathy: From Phenotype and Pathogenesis to Treatment","volume":"8","author":"Cheng","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1253\/circj.CJ-20-0027","article-title":"Lifelong Clinical Impact of the Presence of Sarcomere Gene Mutation in Japanese Patients With Hypertrophic Cardiomyopathy","volume":"84","author":"Nakashima","year":"2020","journal-title":"Circ. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.hlc.2021.04.008","article-title":"Fibrosis in Hypertrophic Cardiomyopathy Patients with and Without Sarcomere Gene Mutations","volume":"30","author":"Vullaganti","year":"2021","journal-title":"Heart Lung Circ."},{"key":"ref_19","first-page":"1397","article-title":"Long-term outcomes and left ventricular diastolic function of sarcomere mutation-positive and mutation-negative patients with hypertrophic cardiomyopathy: A prospective cohort study","volume":"22","author":"Chen","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/heartjnl-2014-306387","article-title":"Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy","volume":"101","author":"Lopes","year":"2015","journal-title":"Heart"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e001620","DOI":"10.1161\/CIRCGENETICS.116.001620","article-title":"Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications","volume":"10","author":"Ingles","year":"2017","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1161\/CIRCULATIONAHA.110.978924","article-title":"Genetics and clinical destiny: Improving care in hypertrophic cardiomyopathy","volume":"122","author":"Ho","year":"2010","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/gim.2014.205","article-title":"Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: Expanded panels offer limited additional sensitivity","volume":"17","author":"Alfares","year":"2015","journal-title":"Genet. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1093\/eurheartj\/ehab424","article-title":"Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy","volume":"42","author":"Lopes","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.hrthm.2019.07.014","article-title":"Making the case for cascade screening among families with inherited heart disease","volume":"17","author":"Ingles","year":"2020","journal-title":"Heart Rhythm"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Teekakirikul, P., Zhu, W., Huang, H.C., and Fung, E. (2019). Hypertrophic Cardiomyopathy: An Overview of Genetics and Management. Biomolecules, 9.","DOI":"10.3390\/biom9120878"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cge.13027","article-title":"Genetics of hypertrophic cardiomyopathy: A review of current state","volume":"93","author":"Gimeno","year":"2018","journal-title":"Clin. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/heartjnl-2014-307205","article-title":"Phenotype and prognostic correlations of the converter region mutations affecting the \u03b2 myosin heavy chain","volume":"101","author":"Arad","year":"2015","journal-title":"Heart"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1017\/S1047951119002701","article-title":"A novel MYBPC3 c.2737+1 (IVS26) G>T mutation responsible for high-risk hypertrophic cardiomyopathy","volume":"30","author":"Tong","year":"2020","journal-title":"Cardiol. Young"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2009.11.062","article-title":"Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations","volume":"55","author":"Girolami","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/hmg\/ddab249","article-title":"A genome-first approach to rare variants in hypertrophic cardiomyopathy genes MYBPC3 and MYH7 in a medical biobank","volume":"31","author":"Park","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1093\/hmg\/ddn160","article-title":"Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy","volume":"17","author":"Geier","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_33","first-page":"3461","article-title":"Defining the genetic architecture of hypertrophic cardiomyopathy: Re-evaluating the role of non-sarcomeric genes","volume":"38","author":"Walsh","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Stern, J.A., Markova, S., Ueda, Y., Kim, J.B., Pascoe, P.J., Evanchik, M.J., Green, E.M., and Harris, S.P. (2016). A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168407"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): Health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1001\/jamacardio.2022.5099","article-title":"Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial","volume":"8","author":"Wheeler","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ejhf.2737","article-title":"Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy","volume":"25","author":"Wheeler","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e014986","DOI":"10.1161\/CIRCIMAGING.122.014986","article-title":"Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study","volume":"15","author":"Cremer","year":"2022","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"101429","DOI":"10.1016\/j.cpcardiol.2022.101429","article-title":"Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"48","author":"Ismayl","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/heartjnl-2022-322271","article-title":"Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy","volume":"109","author":"Farrant","year":"2023","journal-title":"Heart"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e001803","DOI":"10.1136\/openhrt-2021-001803","article-title":"Copper chelation in patients with hypertrophic cardiomyopathy","volume":"9","author":"Reid","year":"2022","journal-title":"Open Heart"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.jtcvs.2021.04.001","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"162","author":"Ommen","year":"2021","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/mt.2014.127","article-title":"Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure","volume":"22","author":"Ishikawa","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40119-022-00283-5","article-title":"Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy","volume":"11","author":"Packard","year":"2022","journal-title":"Cardiol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1161\/01.RES.0000147312.02673.56","article-title":"Binding of myosin binding protein-C to myosin subfragment S2 affects contractility independent of a tether mechanism","volume":"95","author":"Harris","year":"2004","journal-title":"Circ. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1085\/jgp.200810013","article-title":"Contribution of the myosin binding protein C motif to functional effects in permeabilized rat trabeculae","volume":"132","author":"Razumova","year":"2008","journal-title":"J. Gen. Physiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e130182","DOI":"10.1172\/jci.insight.130182","article-title":"AAV9 gene transfer of cMyBPC N-terminal domains ameliorates cardiomyopathy in cMyBPC-deficient mice","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1096\/fj.08-118182","article-title":"Malignant familial hypertrophic cardiomyopathy D166V mutation in the ventricular myosin regulatory light chain causes profound effects in skinned and intact papillary muscle fibers from transgenic mice","volume":"23","author":"Kerrick","year":"2009","journal-title":"FASEB J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00109-019-01791-z","article-title":"Therapeutic potential of AAV9-S15D-RLC gene delivery in humanized MYL2 mouse model of HCM","volume":"97","author":"Yadav","year":"2019","journal-title":"J. Mol. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41434-023-00384-3","article-title":"Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy","volume":"30","author":"Nie","year":"2023","journal-title":"Gene Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-022-02176-5","article-title":"Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice","volume":"29","author":"Chai","year":"2023","journal-title":"Nat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry\u2019s disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/jmg-2022-108523","article-title":"Prevalence of Fabry disease-causing variants in the UK Biobank","volume":"60","author":"Gilchrist","year":"2023","journal-title":"J. Med. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2147\/TCRM.S247814","article-title":"Diagnosis and Screening of Patients with Fabry Disease","volume":"16","author":"Vardarli","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00439-008-0560-2","article-title":"Identifying modifier genes of monogenic disease: Strategies and difficulties","volume":"124","author":"Genin","year":"2008","journal-title":"Hum. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Ruiz Ram\u00edrez, A.V., Prado Montes de Oca, E., and Figuera, L.E. (2022). Prediction of Regulatory SNPs in Putative Minor Genes of the Neuro-Cardiovascular Variant in Fabry Reveals Insights into Autophagy\/Apoptosis and Fibrosis. Biology, 11.","DOI":"10.3390\/biology11091287"},{"key":"ref_69","first-page":"3733","article-title":"Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry disease","volume":"15","author":"Ouyang","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Boutin, M., Lavoie, P., Beaudon, M., Kabala Ntumba, G., Bichet, D.G., Maranda, B., and Auray-Blais, C. (2023). Mass Spectrometry Analysis of Globotriaosylsphingosine and Its Analogues in Dried Blood Spots. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043223"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e008872","DOI":"10.1161\/CIRCIMAGING.119.008872","article-title":"Quantitative Myocardial Perfusion in Fabry Disease","volume":"12","author":"Knott","year":"2019","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2174\/138161282104141204142643","article-title":"The Fabry cardiomyopathy\u2014Diagnostic approach and current treatment","volume":"21","author":"Weidemann","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.carpath.2018.11.002","article-title":"Lysosomal storage disorders affecting the heart: A review","volume":"39","author":"Nair","year":"2019","journal-title":"Cardiovasc. Pathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/qjmed\/hcy120","article-title":"Diagnosis and treatment of the cardiovascular consequences of Fabry disease","volume":"112","author":"Baig","year":"2019","journal-title":"QJM"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/hrt.2005.063818","article-title":"The heart in Anderson-Fabry disease and other lysosomal storage disorders","volume":"93","author":"Linhart","year":"2007","journal-title":"Heart"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: Formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur. Heart J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: Potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur. Heart J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jjcc.2007.12.001","article-title":"Terminal stage cardiac findings in patients with cardiac Fabry disease: An electrocardiographic, echocardiographic, and autopsy study","volume":"51","author":"Takenaka","year":"2008","journal-title":"J. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: Evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e027041","DOI":"10.1161\/JAHA.122.027041","article-title":"Left Ventricular Apical Aneurysm in Fabry Disease: Implications for Clinical Significance and Risk Stratification","volume":"12","author":"Chang","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/europace\/eur267","article-title":"Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease","volume":"13","author":"Coats","year":"2011","journal-title":"Europace"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fcvm.2016.00007","article-title":"Electrocardiographic Changes and Arrhythmia in Fabry Disease","volume":"3","author":"Namdar","year":"2016","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0002-8703(77)80064-1","article-title":"Electrocardiographic and vectorcardiographic abnormalities in Fabry\u2019s disease","volume":"93","author":"Mehta","year":"1977","journal-title":"Am. Heart J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ahj.2020.04.006","article-title":"Predictors of Fabry disease in patients with hypertrophic cardiomyopathy: How to guide the diagnostic strategy?","volume":"226","author":"Azevedo","year":"2020","journal-title":"Am. Heart J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Yim, J., Yau, O., Yeung, D.F., and Tsang, T.S.M. (2021). Fabry Cardiomyopathy: Current Practice and Future Directions. Cells, 10.","DOI":"10.3390\/cells10061532"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","article-title":"Lentivirus-mediated gene therapy for Fabry disease","volume":"12","author":"Khan","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","article-title":"Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry","volume":"12","author":"Watt","year":"2010","journal-title":"Genet. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1681\/ASN.2018030329","article-title":"Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"126","DOI":"10.7150\/ijms.66448","article-title":"Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis","volume":"19","author":"Lee","year":"2022","journal-title":"Int. J. Med. Sci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ehf2.12647","article-title":"Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: A pre-treatment vs. post-treatment analysis","volume":"7","author":"Wanner","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"100454","DOI":"10.1016\/j.ymgmr.2019.100454","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/gim.2016.117","article-title":"Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: A systematic review and meta-analysis of the literature","volume":"19","author":"Pisani","year":"2017","journal-title":"Genet. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e1684","DOI":"10.1002\/wnan.1684","article-title":"Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease","volume":"13","author":"Abasolo","year":"2021","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jimd.12228","article-title":"Developments in the treatment of Fabry disease","volume":"43","author":"Hollak","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Frustaci, A., Najafian, B., Donato, G., Verardo, R., Chimenti, C., Sansone, L., Belli, M., Vernucci, E., and Russo, M.A. (2022). Divergent Impact of Enzyme Replacement Therapy on Human Cardiomyocytes and Enterocytes Affected by Fabry Disease: Correlation with Mannose-6-phosphate Receptor Expression. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051344"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Frustaci, A., Verardo, R., Scialla, R., Bagnato, G., Verardo, M., Alfarano, M., and Russo, M.A. (2022). Downregulation of Mannose-6-Phosphate Receptors in Fabry Disease Cardiomyopathy: A Potential Target for Enzyme Therapy Enhancement. J. Clin. Med., 11.","DOI":"10.3390\/jcm11185440"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","article-title":"Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1\/2 clinical trial","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.ymgme.2019.11.249","article-title":"Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study","volume":"129","author":"Linhart","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Weidemann, F., Jovanovic, A., Herrmann, K., and Vardarli, I. (2022). Chaperone Therapy in Fabry Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031887"},{"key":"ref_105","first-page":"S111","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: In vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","article-title":"Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)","volume":"8","author":"Lenders","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"106981","DOI":"10.1016\/j.ymgme.2022.106981","article-title":"Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter study","volume":"138","author":"Muntze","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/jmg-2022-108669","article-title":"Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes","volume":"60","author":"Hughes","year":"2023","journal-title":"J. Med. Genet."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jmg-2022-108768","article-title":"Effect of Migalastat on cArdiac Involvement in FabRry Disease: MAIORA study","volume":"60","author":"Camporeale","year":"2023","journal-title":"J. Med. Genet."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ndt\/gfab038","article-title":"Precision medicine in Fabry disease","volume":"36","author":"Lenders","year":"2021","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","article-title":"Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease","volume":"21","author":"Ashe","year":"2015","journal-title":"Mol. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"BSR20160402","DOI":"10.1042\/BSR20160402","article-title":"Case study on the pathophysiology of Fabry disease: Abnormalities of cellular membranes can be reversed by substrate reduction in vitro","volume":"37","author":"Brogden","year":"2017","journal-title":"Biosci. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","article-title":"Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement","volume":"103","author":"Guerard","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"100862","DOI":"10.1016\/j.ymgmr.2022.100862","article-title":"Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study","volume":"31","author":"Wanner","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.865","article-title":"Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers","volume":"10","author":"Peterschmitt","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"106963","DOI":"10.1016\/j.ymgme.2022.11.002","article-title":"Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study","volume":"138","author":"Deegan","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Rodriguez-Castejon, J., Gomez-Aguado, I., Beraza-Millor, M., Solinis, M.A., Del Pozo-Rodriguez, A., and Rodriguez-Gascon, A. (2022). Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease. Nanomaterials, 12.","DOI":"10.3390\/nano12142339"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.omtm.2020.07.002","article-title":"AAV2\/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction","volume":"18","author":"Yasuda","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","article-title":"Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy","volume":"27","author":"DeRosa","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41434-022-00381-y","article-title":"Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease","volume":"30","author":"Jeyakumar","year":"2023","journal-title":"Gene. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"Hop","year":"2003","journal-title":"Pediatrics"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1067\/mpd.2000.107112","article-title":"Identification of two subtypes of infantile acid maltase deficiency","volume":"137","author":"Slonim","year":"2000","journal-title":"J. Pediatr."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/GIM.0b013e3181d2900e","article-title":"The angiotensin-converting enzyme insertion\/deletion polymorphism modifies the clinical outcome in patients with Pompe disease","volume":"12","author":"Ravaglia","year":"2010","journal-title":"Genet. Med."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Kuperus, E., van der Meijden, J.C., In \u2018t Groen, S.L.M., Kroos, M.A., Hoogeveen-Westerveld, M., Rizopoulos, D., Martinez, M.Y.N., Kruijshaar, M.E., van Doorn, P.A., and van der Beek, N. (2018). The ACE I\/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0208854"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1042\/bj2720493","article-title":"Characterization of the human lysosomal alpha-glucosidase gene","volume":"272","author":"Hoefsloot","year":"1990","journal-title":"Biochem. J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/hmg\/3.12.2231","article-title":"Aberrant splicing in adult onset glycogen storage disease type II (GSDII): Molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation","volume":"3","author":"Huie","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"ref_131","first-page":"887","article-title":"Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II","volume":"56","author":"Boerkoel","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/hmg\/5.7.995","article-title":"A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II)","volume":"5","author":"Raben","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2009.03.004","article-title":"High frequency of acid alpha-glucosidase pseudodeficiency complicates newborn screening for glycogen storage disease type II in the Japanese population","volume":"97","author":"Kumamoto","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ymgme.2009.12.014","article-title":"Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program","volume":"99","author":"Labrousse","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: Major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/8904_2014_392","article-title":"Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany","volume":"20","author":"Hahn","year":"2015","journal-title":"JIMD Rep."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10545-010-9206-3","article-title":"Treatment of infantile Pompe disease with alglucosidase alpha: The UK experience","volume":"33","author":"Chakrapani","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijcard.2023.03.010","article-title":"Effects of enzyme replacement therapy on cardiac function in classic infantile Pompe disease","volume":"380","author":"Scheffers","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","article-title":"Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: An open-label single-center study","volume":"39","author":"Poelman","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2352-4642(21)00308-4","article-title":"Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: A multicentre observational cohort study from the European Pompe Consortium","volume":"6","author":"Ditters","year":"2022","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","article-title":"Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years","volume":"259","author":"Angelini","year":"2012","journal-title":"J. Neurol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","article-title":"Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II","volume":"33","author":"Bembi","year":"2010","journal-title":"J. Inherit Metab. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.nmd.2010.07.277","article-title":"Effect of enzyme therapy in juvenile patients with Pompe disease: A three-year open-label study","volume":"20","author":"Hagemans","year":"2010","journal-title":"Neuromuscul. Disord."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J. Neurol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","article-title":"Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa","volume":"107","author":"Barohn","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.21025","article-title":"Clinical features of late-onset Pompe disease: A prospective cohort study","volume":"38","author":"Wokke","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease","volume":"362","author":"Clemens","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1017\/S1047951121002079","article-title":"Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort","volume":"32","author":"Byrne","year":"2022","journal-title":"Cardiol. Young"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00415-021-10526-5","article-title":"Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: A systematic review and a meta-analysis","volume":"269","author":"Sarah","year":"2022","journal-title":"J. Neurol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13023-023-02715-4","article-title":"Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study","volume":"18","author":"Ditters","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2200587","article-title":"In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe\u2019s Disease","volume":"387","author":"Cohen","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/dmcn.13740","article-title":"Classic infantile Pompe patients approaching adulthood: A cohort study on consequences for the brain","volume":"60","author":"Ebbink","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: The Dutch experience in classic infantile Pompe disease","volume":"38","author":"Kroos","year":"2015","journal-title":"J. Inherit Metab. Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","article-title":"Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naive and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"100328","DOI":"10.1016\/j.gim.2022.10.010","article-title":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report","volume":"25","author":"Kishnani","year":"2023","journal-title":"Genet. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): A phase 3, randomised, multicentre trial","volume":"20","author":"Kishnani","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2023.0552","article-title":"Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial","volume":"80","author":"Kishnani","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrm1050","article-title":"Mannose 6-phosphate receptors: New twists in the tale","volume":"4","author":"Ghosh","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2017.10.043","article-title":"Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid alpha-glucosidase","volume":"269","author":"Basile","year":"2018","journal-title":"J. Control Release"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymgme.2011.11.005","article-title":"beta2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease","volume":"105","author":"Koeberl","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2011.02.006","article-title":"Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle","volume":"103","author":"Koeberl","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1096\/fj.13-241893","article-title":"Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease","volume":"28","author":"Koeberl","year":"2014","journal-title":"FASEB J."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ymgme.2019.12.008","article-title":"Improved muscle function in a phase I\/II clinical trial of albuterol in Pompe disease","volume":"129","author":"Koeberl","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.ymthe.2018.06.023","article-title":"Correction of Biochemical Abnormalities and Improved Muscle Function in a Phase I\/II Clinical Trial of Clenbuterol in Pompe Disease","volume":"26","author":"Koeberl","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1038\/mt.2014.138","article-title":"A chaperone enhances blood alpha-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy","volume":"22","author":"Parenti","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e125358","DOI":"10.1172\/jci.insight.125358","article-title":"Improved efficacy of a next-generation ERT in murine Pompe disease","volume":"4","author":"Xu","year":"2019","journal-title":"JCI Insight"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): An international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","article-title":"Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery","volume":"19","author":"Fu","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.gt.3300609","article-title":"Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle","volume":"5","author":"Pauly","year":"1998","journal-title":"Gene. Ther."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1073\/pnas.96.16.8861","article-title":"Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase","volume":"96","author":"Amalfitano","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1006\/mthe.2002.0580","article-title":"Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors","volume":"5","author":"Fraites","year":"2002","journal-title":"Mol. Ther."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ymthe.2005.01.012","article-title":"Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter","volume":"11","author":"Sun","year":"2005","journal-title":"Mol. Ther."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/mt.2013.282","article-title":"Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice","volume":"22","author":"Elmallah","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/mt.2009.305","article-title":"Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease","volume":"18","author":"Mah","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.mt.6300100","article-title":"Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors","volume":"15","author":"Mah","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/humc.2017.146","article-title":"Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease","volume":"28","author":"Corti","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.expneurol.2016.07.013","article-title":"Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity","volume":"287","author":"Smith","year":"2017","journal-title":"Exp. Neurol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/humc.2014.2514","article-title":"Phase I\/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease","volume":"25","author":"Byrne","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: Initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/humc.2015.068","article-title":"Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning","volume":"26","author":"Corti","year":"2015","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"15007","DOI":"10.1038\/mtm.2015.7","article-title":"Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice","volume":"2","author":"Falk","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/mt.2013.96","article-title":"Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease","volume":"21","author":"Falk","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/mt.2009.195","article-title":"Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease","volume":"18","author":"Sun","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","article-title":"Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction","volume":"4","author":"Han","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"eaam6375","DOI":"10.1126\/scitranslmed.aam6375","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid alpha-glucosidase","volume":"9","author":"Puzzo","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.ymthe.2023.02.014","article-title":"Phase I study of liver depot gene therapy in late-onset Pompe disease","volume":"31","author":"Smith","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/mus.21811","article-title":"Functional performance and muscle strength phenotypes in men and women with Danon disease","volume":"42","author":"Kramer","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijcard.2019.01.020","article-title":"Danon disease: Gender differences in presentation and outcomes","volume":"286","author":"Brambatti","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/CIRCHEARTFAILURE.114.001105","article-title":"Danon disease: Clinical features, evaluation, and management","volume":"7","author":"Levandowski","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/GIM.0b013e31820ad795","article-title":"Natural history of Danon disease","volume":"13","author":"Boucek","year":"2011","journal-title":"Genet. Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1161\/01.CIR.0000075270.13497.2B","article-title":"Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy","volume":"107","author":"Arad","year":"2003","journal-title":"Circulation"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1002\/mgg3.638","article-title":"Prevalence and clinical characteristics of Danon disease among patients with left ventricular hypertrophy and concomitant electrocardiographic preexcitation","volume":"7","author":"Liu","year":"2019","journal-title":"Mol. Genet. Genomic. Med."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/hrt.2003.029504","article-title":"Danon\u2019s disease as a cause of hypertrophic cardiomyopathy: A systematic survey","volume":"90","author":"Charron","year":"2004","journal-title":"Heart"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1161\/CIRCULATIONAHA.105.546481","article-title":"Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children","volume":"112","author":"Yang","year":"2005","journal-title":"Circulation"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.amjcard.2016.06.037","article-title":"Identification of LAMP2 Mutations in Early-Onset Danon Disease With Hypertrophic Cardiomyopathy by Targeted Next-Generation Sequencing","volume":"118","author":"Fu","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/s10038-018-0479-y","article-title":"Genetic background of Japanese patients with pediatric hypertrophic and restrictive cardiomyopathy","volume":"63","author":"Hayashi","year":"2018","journal-title":"J. Hum. Genet."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.hrthm.2019.07.019","article-title":"The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy","volume":"17","author":"Finocchiaro","year":"2020","journal-title":"Heart Rhythm"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41436-018-0046-0","article-title":"Defining the diagnostic effectiveness of genes for inclusion in panels: The experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center","volume":"21","author":"Mazzarotto","year":"2019","journal-title":"Genet. Med."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/WNL.31.1.51","article-title":"Lysosomal glycogen storage disease with normal acid maltase","volume":"31","author":"Danon","year":"1981","journal-title":"Neurology"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1212\/01.wnl.0000309219.61785.b3","article-title":"Extension of the clinical spectrum of Danon disease","volume":"70","author":"Aronica","year":"2008","journal-title":"Neurology"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.nmd.2005.02.008","article-title":"Asymptomatic hyperCKemia in a case of Danon disease due to a missense mutation in Lamp-2 gene","volume":"15","author":"Musumeci","year":"2005","journal-title":"Neuromuscul. Disord."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5414\/NP300465","article-title":"Danon disease caused by two novel mutations of the LAMP2 gene: Implications for two ends of the clinical spectrum","volume":"31","author":"Hong","year":"2012","journal-title":"Clin. Neuropathol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"763240","DOI":"10.3389\/fcvm.2021.763240","article-title":"Case Report: A Novel LAMP2 Splice-Altering Mutation Causes Cardiac-Only Danon Disease","volume":"8","author":"Li","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/35022604","article-title":"Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease)","volume":"406","author":"Nishino","year":"2000","journal-title":"Nature"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1073\/pnas.1808618116","article-title":"LAMP-2B regulates human cardiomyocyte function by mediating autophagosome-lysosome fusion","volume":"116","author":"Chi","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.yjmcc.2017.05.007","article-title":"Impaired mitophagy facilitates mitochondrial damage in Danon disease","volume":"108","author":"Hashem","year":"2017","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1002\/stem.2015","article-title":"Brief Report: Oxidative Stress Mediates Cardiomyocyte Apoptosis in a Human Model of Danon Disease and Heart Failure","volume":"33","author":"Hashem","year":"2015","journal-title":"Stem Cells"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/nan.12587","article-title":"Review: Danon disease: Review of natural history and recent advances","volume":"46","author":"Cenacchi","year":"2020","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_213","first-page":"284","article-title":"Novel LAMP2 mutations in Chinese patients with Danon disease cause varying degrees of clinical severity","volume":"33","author":"Luo","year":"2014","journal-title":"Clin. Neuropathol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1161\/CIRCGENETICS.109.901785","article-title":"LAMP2 microdeletions in patients with Danon disease","volume":"3","author":"Yang","year":"2010","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/ehf2.14417","article-title":"Identification of a novel splicing-altering LAMP2 variant in a Chinese family with Danon disease","volume":"10","author":"Fu","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"A10727","DOI":"10.1161\/circ.144.suppl_1.10727","article-title":"Abstract 10727: Results from First-in-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease","volume":"144","author":"Greenberg","year":"2021","journal-title":"Circulation"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"eaax1744","DOI":"10.1126\/scitranslmed.aax1744","article-title":"Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease","volume":"12","author":"Manso","year":"2020","journal-title":"Sci. Transl. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/17\/13239\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:39:35Z","timestamp":1760128775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/17\/13239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,26]]},"references-count":217,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["ijms241713239"],"URL":"https:\/\/doi.org\/10.3390\/ijms241713239","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,26]]}}}